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TheMICs andminimum bactericidal concentrations (MBCs) for the biocides benzalkonium chloride and chlorhexidine were
determined against 1,602 clinical isolates of Staphylococcus aureus. Both compounds showed unimodal MIC andMBC distribu-
tions (2 and 4 or 8 mg/liter, respectively) with no apparent subpopulation with reduced susceptibility. To investigate further, all
isolates were screened for qac genes, and 39 of these also had the promoter region of the NorAmultidrug-resistant (MDR) efflux
pump sequenced. The presence of qacA, qacB, qacC, and qacG genes increased the modeMIC, but not MBC, to benzalkonium
chloride, while only qacA and qacB increased the chlorhexidine modeMIC. Isolates with a wild-type norA promoter or muta-
tions in the norA promoter had similar biocide MIC distributions; notably, not all clinical isolates with norAmutations were
resistant to fluoroquinolones. In vitro efflux mutants could be readily selected with ethidium bromide and acriflavine. Multiple
passages were necessary to select mutants with biocides, but these mutants showed phenotypes comparable to those of mutants
selected by dyes. All mutants showed changes in the promoter region of norA, but these were distinct from this region of the clin-
ical isolates. Still, none of the in vitromutants displayed fitness defects in a killing assay in Galleria mellonella larvae. In conclu-
sion, our data provide an in-depth comparative overview on efflux in S. aureusmutants and clinical isolates, showing also that
plasmid-encoded efflux pumps did not affect bactericidal activity of biocides. In addition, current in vitro tests appear not to be
suitable for predicting levels of resistance that are clinically relevant.
Antimicrobial compounds, which include antibiotics, are al-most exclusively intended for direct human or animal use.
Biocides, on the other hand, have a much wider range of applica-
tion, including disinfectants, preservatives, pest control agents,
and other products (1). Despite the continuous and widespread
use of biocides, detailed information on possible resistance mech-
anisms in clinical isolates is still lacking (2–4).
Active efflux is one of the main mechanisms of resistance to
antibiotics and biocides. All bacteria have efflux systems which
share a broad substrate specificity, including cationic biocide
compounds. These transporters are known as multidrug-resistant
(MDR) efflux pumps and belong to distinct transporter families
(5). NorA is the chromosomally encoded MDR efflux pump in
Staphylococcus aureus (6), with norfloxacin (NOR) and cipro-
floxacin (CIP) being the most clinically relevant substrates
(7). NorA also confers resistance to a broad range of other
compounds, including lipophilic, monocationic compounds
(ethidium bromide [EB], cetrimide, benzalkonium chloride
[BZC], and acriflavine [AF]) (8, 9). NorA-induced resistance typ-
ically arises from increased expression of the efflux gene due to
mutations in the norA promoter region (10–12).
Of the plasmid-encoded MDR efflux pumps, 6 different qac
genes have been described in S. aureus (qacA, qacB, qacC, qacG,
qacH, and qacJ) (13–18). Among these, the most frequently en-
countered pump is the QacA protein, which mediates resistance to
a number of classes of antimicrobial organic cations, including
intercalating dyes (e.g., ethidium bromide and acriflavine) and
quaternary ammonium compounds (QAC) (13). Next in fre-
quency of detection is the qacC gene, which encodes a small mem-
brane efflux protein of the SMR family and has a more restricted
substrate profile (14). QacB protein, similar to QacA except for
seven nucleotide polymorphisms, confers reduced susceptibility
to diamidines and biguanides (15). Other plasmid-located qac
genes, qacG, qacH, and qacJ, have been identified in food-borne
and veterinary isolates of S. aureus (16–18). Being located on plas-
mids, the qac genes can be transferred horizontally, and strains
carrying qac genes have been isolated worldwide (19).
It has been suggested that widespread use of biocides affects the
prevalence of antibiotic-resistant microorganisms (2, 20, 21). The
increased number of formulations/products containing biocides,
often at low concentration, raises concerns over the risk of selec-
tion of biocide-resistant strains (2, 20, 21). By mechanisms of
coresistance and cross-resistance, such strains also could become
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antibiotic resistant and possibly represent a problem of clinical
relevance (2, 20, 21). In this context, recent guidelines and policies
aim to introduce tests for risk assessment for biocide resistance
development. Still, no standardized methodology is available to
run such tests. In the case of the biocide triclosan, we recently
demonstrated the low predictive value of the in vitro test to predict
clinically relevant biocide resistance (22). The aim of the present
work is to provide insight into the factors to be taken into account
for a risk analysis of resistance to the widely used quaternary am-
monium compounds and bisbiguanides. For this scope, we per-
formed a comparative molecular and phenotypic characterization
of the susceptibility to benzalkonium chloride and chlorhexidine
(CHX) in the clinically relevant model organism S. aureus. This
work is part of the multicenter BIOHYPO project, which aims to
evaluate the impact of biocide use in the food chain on antimicro-
bial drug resistance of clinical relevance in enterobacteria, Gram-
negative nonfermenters, staphylococci, enterococci, lactic acid
bacteria, and fungi (2, 22–27). In this context, the detailed char-
acterization of biocide susceptibility phenotypes and genotypes is
the first step of correlation of these data with antimicrobial resis-
tance profiles.
MATERIALS AND METHODS
Bacterial strains. A collection of 1,602 S. aureus strains collected in 2002
to 2003 from different geographical origins, representing both hospital-
and community-acquired infections and hosted at the strain collection of
Quotient Bioresearch (Fordham, United Kingdom), was investigated.
The same strain collection had previously been screened for susceptibility
to the biocide triclosan (22). S. aureus strains used for in vitro mutant
selection included the biocide reference strain ATCC 6538, the standard
laboratory strain RN4220, the classical reference strain for antimicrobial
susceptibility testing, ATCC 2593, and three methicillin-resistant S. au-
reus (MRSA) strains with sequenced genomes, MW2, COL, and Mu50, of
which the latter two harbor plasmids containing the quaternary ammo-
nium compound resistance gene (qacA) (22).
Chemical agents. Compounds used were ethidium bromide (EB; 10
mg/ml; Fluka, Steinheim, Germany), ciprofloxacin (CIP; 2 mg/ml; Bayer,
Leverkusen, Germany), norfloxacin (NOR; 50 mg/ml in acetic acid;
N9890; Sigma, Steinheim, Germany), benzalkonium chloride (BZC; 100
mg/ml in water; B6295; Sigma), chlorhexidine digluconate (CHX; 100
mg/ml in water; C9394; Sigma), and acriflavine (AF; 100 mg/ml in di-
methylsulfoxide [DMSO]; A8126; Sigma).
Susceptibility testing. MICs were determined using the broth mi-
crodilution method (28). Minimum bactericidal concentrations (MBCs)
were determined by subculturing 10 l from each well without visible
bacterial growth on Mueller-Hinton agar plates. After 24 h of incubation
at 37°C, the dilution yielding three colonies or fewer was scored as the
MBC, as described by the CLSI for starting inocula of 1  105 CFU/ml
(29). Reference strains were included in all 105 MIC and MBC determi-
nations, and we confirmed the reliability of the susceptibility tests for the
biocidal compounds by evidencing deviations from the mean results of
only one dilution.
MLST analysis. Multilocus sequence typing (MLST) was performed
on a group of 91 clinical isolates carrying qac determinants as described
previously (30). The allelic number and STs were assigned using the S.
aureus MLST database (http://saureus.mlst.net), while the clustering of
related STs, defined as clonal complexes (CCs), was analyzed with the
BURST algorithm (http://eburst.mlst.net). New alleles and STs have been
submitted to the S. aureus MLST database.
Activity testing. Benzalkonium chloride and chlorhexidine activity
testing against the reference S. aureus strain and selected isolates were
performed by following EN 1276 (31). Briefly, 1 ml of a test suspension of
microorganisms at a concentration between 1.5  108 and 5  108
CFU/ml was mixed with albumin from the bovine serum Cohn V fraction
(A2153; Sigma) at a concentration of 0.03 g/liter. After 2 min, 8 ml of the
test product solution was added and mixed. Test product solutions were
obtained by diluting benzalkonium chloride (B6295; Sigma) and chlo-
rhexidine digluconate (C9394; Sigma) in hard water (119 mg/liter MgCl2,
277 mg/liter CaCl2, and 280 mg/liter NaHCO3). The mixture was main-
tained at 20°C (1°C) in the test tube for 5 min (10 s). After this contact
time, a 1-ml aliquot from the test tube was transferred to a tube containing
8 ml of the neutralizer (3 g/liter lecithin, 30 g/liter polysorbate-80, 5 g/liter
sodium thiosulfate, 1 g/liter L-histidine, and 30 g/liter saponin in diluent)
and 1 ml of water. After 5 min of neutralization, dilutions of the neutral-
ized suspension were performed in diluent (0.14 mM NaCl plus 0.1%
tryptone). One ml of each dilution, ranging from the neutralized suspen-
sion to a 103 dilution, was cultured in duplicate on tryptic soy agar (TSA;
Liofilchem, Roseto degli Abruzzi, Italy) using the pour plate technique.
Plates were incubated at 37°C (1°C) for 48 h. Calculations of log reduc-
tions and expression of results followed the provisions of European Stan-
dard (EN) methods (31).
Selection of mutants. For selection of single-exposure mutants,
strains were grown overnight and approximately 1011 CFU was plated on
TSA containing either ethidium bromide (64 mg/liter), acriflavine (64
mg/liter), benzalkonium chloride (16 mg/liter), or chlorhexidine (8 mg/
liter). Plates were examined for growth after 48 h. Multiple-exposure mu-
tants were produced by five serial passages on plates containing increasing
concentrations from 1 to 16 mg/liter of benzalkonium chloride and 0.5 to
8 mg/liter of chlorhexidine. Single colonies obtained by both methods
were randomly selected for further analyses.
Qualitative real-time PCR amplification of qac genes. Genomic
DNA was extracted using the High Pure PCR template preparation kit
(Roche Diagnostics, Germany). Separate fragments of DNA internal to
each of four qac genes were amplified by real-time PCR using the primers
described in Table S1 in the supplemental material and SYBR green I dye
(Roche Diagnostics, Germany). Two TaqMan probes with two different
fluorophores at the 5= end and a minor groove binder (MGB) at the 3= end
(Applied Biosystems, United Kingdom) were used in order to distinguish
between qacA and qacB. Qualitative real-time PCRs were performed in a
LightCycler 480 system (Roche Diagnostics, Germany). The two qacB-
positive strains were confirmed by sequencing with the Sanger method
(BMR Genomics, University of Padova, Italy).
Screening of thenorA promoter region.A 457-bp region upstream of
norA in a subset of 49 clinical isolates was amplified using primers
NorAp_F and NorAp_R (see Table S1 in the supplemental material) and
was designed on the basis of the S. aureus MW2 chromosome using stan-
dard procedures. Strains were selected to be representative of the full
range of ethidium bromide MICs. PCR fragments were submitted for
sequencing to BMR Genomics (University of Padova, Italy). The nucleo-
tide positions of intergenic regions are numbered backwards, starting at
the norA start codon (NC_003923, position 739144).
Whole-genome sequencing. Four clinical isolates with benzalkonium
chloride MBCs of 32 mg/liter and carrying no qac determinants were
sequenced. Whole-genome sequence data were analyzed as described in
Ciusa et al. (22).
Galleriamellonella infectionmodel. As described before, final-instar
larvae of G. mellonella (Allevamento Cirà, Como, Italy) were stored in
wood shavings in the dark at 15°C and used within a week after shipment.
Overnight cultures of S. aureus were resuspended in phosphate-buffered
saline (PBS). G. mellonella was injected with 105 CFU/larva, directly into
the hemocoel via the last left proleg, using a Hamilton syringe (26, 32).
Larvae were incubated at 37°C in petri dishes, and survival was evaluated
for 6 days. Each experimental group contained 16 larvae of appropriate
weight (0.3 to 0.5 g). All experiments included an equal number of larvae
injected with PBS and noninjected larvae. At least three independent as-
says were performed for all G. mellonella killing experiments. Survival
curves were estimated by the Kaplan-Meier method, and differences in
survival were calculated using the log-rank test (STATA 6 software).
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FIG 1 Phenotypic biocide susceptibility profiles of 1,602 S. aureus clinical isolates with genotype indicated. MIC and MBC distributions for benzalkonium
chloride (A and C) and chlorhexidine (E and G) are shown. Molecular characterization of strains is plotted in a color scale, where white stands for the absence
of qacA, qacB, qacC, qacJ, and qacG. The presence of qac determinants is shown in blue for qacA, in green for qacB, in red for qacC, and in yellow for qacG. (B, D,
F, and H) Distribution of qac determinants in a log-scale plot where the color scheme is the same, with the exception of open circles that stand for the absence
of qac genes and black filled circles that represent the total number of strains analyzed. In the case of ethidium bromide (I and J), phenotypic and genotypic data
refer to a subgroup of 245 clinical isolates.
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Statistical analysis. Fisher’s exact test was applied to contingency ta-
bles in order to determine if there were nonrandom associations between
two categorical variables. Spearman’s correlation coefficient, here de-
noted by , measures the nonlinear statistical dependence between two
monotonically dependent samples. The statistical tests were implemented
using Matlab (version 2010b; MathWorks, Natick, MA).
Nucleotide sequence accession numbers. Sequences of the norA pro-
moter regions of 13 clinical isolates (accession numbers JQ744024 to
JQ744036) and 24 laboratory mutants (accession numbers JQ744037 to
JQ744060) were deposited in GenBank.
RESULTS
Susceptibility of clinical isolates to biocides.MIC and MBC data
for benzalkonium chloride and chlorhexidine were obtained from
a series of 1,602 clinical isolates of S. aureus previously character-
ized for their profiles of susceptibility to triclosan (22). Suscepti-
bility data are shown in Fig. 1. Both biocides produced a mode
MIC of 2 mg/liter, with benzalkonium chloride having a mode
MBC of 8 mg/liter and chlorhexidine a mode MBC of 4 mg/liter.
The MIC or MBC distributions were unimodal, without any ob-
vious subpopulation with reduced susceptibility. Only MIC data
for benzalkonium chloride showed the presence of some isolates
which could be considered non-wild type (benzalkonium chloride
MIC of4 mg/liter). The analyses of biocide activity according to
the EN 1276 norm were performed on four clinical isolates, each
carrying either a norApromoter mutation or a qacA, qacC, or qacG
determinant (see below). Data indicate that chlorhexidine is not
less active on strains QBR102278-1191 (qacG), QBR102278-1387
(norA promoter mutation), and QBR102278-2092 (qacC), and it
is not significantly less active on strain QBR102278-1503 (qacA)
(Table 1). Benzalkonium chloride was not less active against the
four isolates tested (Table 2). Out of the 65 strains with low sus-
ceptibility to benzalkonium chloride (MIC of 4 mg/liter), only
six had been found previously to show reduced susceptibility to
triclosan (MBC of4 mg/liter) (22).
Molecular characterization of clinical strains. For a more de-
tailed analysis of the genotypes related to susceptibility to cationic
compounds, the entire collection was analyzed for the presence of
plasmid-encoded efflux pumps. Among the 1,602 strains, 92
(5.7%) were positive for qacA, 5 (0.3%) for qacB, 54 (3.4%) for
qacC, and 1 for qacG. No qacJ-positive strains were found. In two
strains, the qacA and qacC genes were detected concomitantly.
When analyzing the presence of qacdeterminants and related phe-
notypes, data clearly showed that the benzalkonium chloride
mode MIC was increased two dilutions by qacA and one dilution
by the presence of the other qac determinants (Fig. 1B). In other
words, most strains harboring a qacA determinant have a ben-
zalkonium chloride MIC higher by two dilutions than wild-type
staphylococci, while other qac genes determine an increase in MIC
of most strains of only one dilution. The relationship between the
presence of qac genes and a benzalkonium chloride MIC of 4
mg/liter is statistically significant (P  0.001). It is noteworthy
that two out of three strains with the highest MIC to benzalko-
nium chloride (8 mg/liter) were qac negative. The presence of
the four qac genes did not influence the benzalkonium chloride
mode MBC (Fig. 1D). In the case of chlorhexidine, only the pres-
ence of qacA increases the mode MIC values of clinical isolates by
one dilution (Fig. 1F). As for benzalkonium chloride, clinical
strains with low susceptibility to chlorhexidine (MIC of 2 mg/
liter) have a strong relationship with the presence of qacA deter-
minant (P  0.001), and MBC values were not affected by the
presence of qac determinants (Fig. 1H). Correlation between in-
creased MIC values for benzalkonium chloride and for chlorhexi-
dine is statistically significant (P  0.001), as is correlation be-
tween raised MBCs (benzalkonium chloride MBC of16 mg/liter
and chlorhexidine MBC of8 mg/liter) (P 0.001). Since there
was no correlation between qac genes and MBCs (Fig. 1D and H),
we have sequenced the whole genome of four qac-negative strains
with benzalkonium chloride MBCs of32 mg/liter but found no
consistent changes in promoter regions of other efflux pumps (see
Table S2 in the supplemental material).
When plotting ethidium bromide MIC values assayed in a sub-
group of 245 clinical isolates, two clearly separated populations of
strains became evident (Fig. 1I), which was quite distinct from the
unimodal distribution observed for benzalkonium chloride or
TABLE 1 Testing of chlorhexidine activity on S. aureus strains by following CLSI and EN 1276 guidelines
Strain
MIC
(mg/liter)
MBC
(mg/liter)
EN 1276 (log reduction, CFU/ml) guideline ata:
Note10 mg/liter 80 mg/liter 300 mg/liter
ATCC 6538 2 4 0.68 2.70 4.16 Wild type
QBR102278-1191 2 4 1.27 4.84 5.64 qacG positive
QBR102278-1387 2 4 1.14 5.36 5.51 Mutated norA promoter
QBR102278-1503 2 4 1.03 2.16 3.67 qacA positive
QBR102278-2092 2 8 1.30 5.36 5.67 qacC positive
a Values report the logarithmic reduction (log R) of bacterial counts within 5 min of contact time and subsequent neutralization (the product is considered active if log R 5).
TABLE 2 Testing of benzalkonium chloride activity on S. aureus strains by following CLSI and EN 1276 guidelines
Strain MIC (mg/liter) MBC (mg/liter)
EN 1276 (log reduction CFU/ml) guideline ata:
Note10 mg/liter 100 mg/liter 500 mg/liter
ATCC 6538 2 8 1.11 5.48 5.48 Wild type
QBR102278-1191 4 4 1.25 5.52 5.52 qacG positive
QBR102278-1387 4 16 1.24 5.61 5.61 Mutated norA promoter
QBR102278-1503 4 4 1.16 5.53 5.53 qacA positive
QBR102278-2092 8 16 1.17 5.54 5.54 qacC positive
a Values report the logarithmic reduction of bacterial counts within 5 min of contact time and subsequent neutralization (the product is considered active if log R 5).
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chlorhexidine (Fig. 1A and E). In the case of the group of strains
with MICs to ethidium bromide of up to 32 mg/liter, qac determi-
nants were detected only in 12/160 (7.5%) isolates (ethidium bro-
mide-susceptible strains), while clinical strains with low suscepti-
bility to ethidium bromide have a strong association with the
presence of qacA and qacB genes (ethidium bromide MIC of64
mg/liter; P  0.001). The presence of qacA increased the mode
MIC for ethidium bromide by five dilutions (Fig. 1J). The only
qacG-carrying strain showed a MIC value of 64 mg/liter, while the
MIC values of qacC-positive strains did not fall into the group of
ethidium bromide-resistant strains but were distributed around
an intermediate MIC of 32 mg/liter. The distribution of acriflavine
MIC values was similar to that of ethidium bromide (data not
shown).
MLST analysis. Among the 91 clinical isolates analyzed, 84
belonged to 13 previously reported STs, while 7 strains showed a
new ST due to the presence of at least one novel allele or to the
presence of a combination of alleles previously unreported. Al-
most all strains carrying qac genes fell into clonal complex 5, one
of the major lineages of nosocomial MRSA. The detailed data on
MLST are shown in Table S3 in the supplemental material.
Mutant selection and phenotype analysis. Mutants of S. au-
reus ATCC 6538, ATCC 25923, and RN4220 were selected on a
series of cationic antimicrobial substances, including ethidium
bromide, acriflavine, benzalkonium chloride, and chlorhexidine.
Single-exposure mutants could be selected by acriflavine with fre-
quencies of 2.1  109 in RN4220, 1.5  109 in ATCC 25923,
and 5.4 109 in ATCC 6538. A similar frequency was found by
selecting ethidium bromide mutants in ATCC 25923 (2.8 
109), while ethidium bromide mutants had a frequency near the
limit of detection in RN4220 (8.1  1010) and could not be
selected in ATCC 6538 (1.0  1011). For the biocides ben-
zalkonium chloride and chlorhexidine, no single-exposure mu-
tant could be obtained (1.0 1011). The selection of benzalko-
nium chloride and chlorhexidine mutants could be achieved only
by serial passages on agar plates with increasing concentrations of
the biocides (multiple-exposure mutants). Phenotypes of all mu-
tants were comparable irrespective of the selective agent and
showed about an 8-fold increase in both MIC and MBC to
ethidium bromide and acriflavine. For the two biocides benzalko-
nium chloride and chlorhexidine, none of the mutants showed
any increase in MIC. Only a few of the mutants selected by 5
chlorhexidine showed an increase of the MBC to chlorhexidine
only (Table 3). Considering a resistance breakpoint of 1 mg/liter
for ciprofloxacin, all mutants, irrespective of the selective agent,
were fluoroquinolone resistant (Table 3).
Screening ofmutations in thenorApromoter region.All mu-
tants selected in vitro showed mutations in the norA promoter
region (Table 3 and Fig. 2), many of which were described in the
past (9, 11, 33). The T126A mutation, mapping within the 35
site of the predicted norA promoter region, was the most frequent
mutation found (present in 13/24 mutant strains). All in vitro-
selected norA mutants were resistant to norfloxacin (EUCAST eco-
logical cutoff value for susceptibility [ECOFF] for the wild type of4
TABLE 3 Genotypes and phenotypes of mutants for cationic antibacterial compoundsa
Parent and mutant
strain
Selective
agent norA mutation
MIC (mg/liter) MBC (mg/liter)
NOR CIP EB AF CHX BZC NOR CIP EB AF CHX BZC
ATCC 25923 Wild type 1 1 16 32 2 2 8 1 16 64 2 4
MO060 AF A94T 16 8 64 256 4 4 16 8 128 256 8 8
MO061 AF T91A 8 4 32 256 4 4 8 4 64 256 4 4
MO062 AF T126A 8 4 128 256 4 4 16 4 128 256 32 8
MO072 EB T126A 8 4 128 256 4 4 8 4 128 256 4 4
MO058 EB T126A 8 2 128 256 4 4 8 16 128 256 32 16
MO059 EB T126A 8 4 128 256 4 4 8 4 128 256 4 4
ATCC 6538 Wild type 1 0.5 4 16 4 2 2 0.5 16 32 4 8
MO063 AF A107G 8 4 32 128 4 4 8 4 32 256 4 4
MO064 AF T126A 8 2 32 128 4 4 8 4 64 256 4 8
MO065 AF T126A 8 2 32 128 4 4 8 4 64 256 8 4
MO037 CHX T89G 16 4 32 64 8 4 16 4 64 128 128 4
MO038 CHX T89G 16 4 256 256 4 4 16 4 256 256 8 8
MO039 CHX T90G 8 4 256 256 4 4 8 4 256 256 16 8
MO040 CHX T90G 8 4 32 64 4 4 16 4 128 64 32 4
MO041 CHX T90G 8 4 16 256 4 4 8 4 64 256 64 4
RN4220 Wild type 1 0.5 8 16 8 2 2 1 16 32 8 2
MO069 AF A107G 8 4 64 256 4 4 8 4 128 256 8 8
MO070 AF A107G 16 8 64 256 4 4 16 8 128 256 8 8
MO071 AF T126A 8 4 64 128 4 8 16 4 64 256 4 8
MO066 EB T126A 16 4 128 256 4 4 16 8 128 256 8 8
MO067 EB A107G 8 4 64 256 4 4 16 4 128 256 8 8
MO068 EB T126A 16 4 64 256 4 4 16 8 128 256 32 8
MO042 CHX A130C T126A 8 4 256 256 8 4 16 8 256 256 8 4
MO043 CHX A130C T126A 16 4 256 256 8 4 16 8 256 256 32 4
MO044 BZC A130C T126A 16 4 128 256 4 8 16 16 256 256 8 8
MO045 BZC A130C T126A 16 8 128 256 8 4 16 8 128 256 8 8
a NOR, norfloxacin; CIP, ciprofloxacin; EB, ethidium bromide; AF, acriflavine; CHX, chlorhexidine; BZC, benzalkonium chloride.
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mg/liter) and ciprofloxacin (EUCAST clinical breakpoint R 1 mg/
liter). Detection of norA promoter mutations was also performed in
39 clinical isolates, including all 11 qacABCGJ-negative isolates with
EB MICs above 16 mg/liter (Table 4). Twenty-five strains (64%)
carried a wild-type allele, and among them, 9 isolates were qacA or
qacC positive. All clinical strains with norA mutations were resis-
tant to norfloxacin. Irrespective of their MIC to ethidium bro-
mide, four clinical isolates with mutations in the norA promoter
region (QBR102278-1027, QBR102278-1191, QBR102278-2634,
and QBR102278-2635) were susceptible to ciprofloxacin (Table
4). Notably, the majority of clinical strains which showed changes
in norA promoter regions had changes distinct from those found
in mutant strains.
Galleria mellonella infection model. To evaluate if the low
concordance between norA mutations selected in vitro and those
identified in clinical isolates was due to lack of fitness of the labo-
ratory mutants, we performed a virulence test in the greater wax
moth larva (Galleria mellonella) (32). For this analysis, we com-
pared the virulence of the three reference strains, ATCC 6538,
ATCC 25923, and RN4220, to their norA promoter mutants (Fig.
3). No decrease in larvicidal capacity was detected for any of the
mutants. Growth curves of mutants also did not differ from those
of their parental strains (data not shown).
DISCUSSION
Use of biocidal products has increased during recent years, raising
concern about possible biocide resistance and even coresistance
and cross-resistance to antibiotics. The present work addresses the
comparative characterization of efflux mechanisms yielding re-
duced susceptibility to the cationic biocides benzalkonium chlo-
ride and chlorhexidine both in vitro and in clinical isolates of S.
aureus. For the purpose of this study, the standard CLSI MIC and
MBC protocols were adopted. They are the only standardized tests
available to define bacterial resistance, since the normed tests for
biocides are intended to measure activity of the substance or prod-
uct, not the resistance of target organisms (34, 35).
In S. aureus, several transporters involved in biocide efflux
have been reported to date, including plasmid-based QacA, QacB,
QacC, QacG, and QacJ and the chromosomal NorA (8, 13–15, 17,
18). In our collection of 1,602 S. aureus strains of human origin,
the frequencies of qacA (5.7%), qacB (0.3%), qacC (3.4%), and
qacG (0.1%) were consistent with previously reported data (12,
36). In further accordance with published literature, our data
show an increase in the mode MIC of benzalkonium chloride in
the presence of qacA, qacB, qacC, and qacG and also an increase of
chlorhexidine mode MIC in the presence of qacA and qacB. This
variation in growth inhibition is in contrast to the complete ab-
sence of any effect on the cidal activity of biocides. Others had
observed that qac genes confer less than a 2-fold decrease in sus-
ceptibility, which could have been missed by our assays based on
2-fold dilutions. Still, this technical difference does not explain the
absence of any correlation between qac genes and biocide MBC
observed here (37). Our screening underlines that on a very large
set of clinical isolates, none of the qac determinants decreased the
susceptibility to biocides of staphylococci tested according to
CLSI standard bactericidal assays (MBC). The absence of a change
in susceptibility is reflected by the absence of variation in biocide
activity assayed according to the EN 1276 norm. Since there is
absolutely no correlation between increased MBC to both ben-
zalkonium chloride and chlorhexidine and presence of any qac
FIG 2 Schematic map of the intergenic region upstream of norA. Mutations selected in vitro by benzalkonium chloride, chlorhexidine, ethidium bromide, and
acriflavine in strains ATCC 6538, ATCC 25923, and RN4220 are shown above the sequence. Mutations deriving from the analysis of the norA promoter region
of 39 clinical isolates are shown below the sequence. The numbering initiates at the nucleotide in front of the start codon of norA and counts from right to left.
The putative promoter consensus is shown in gray.
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determinant but the correlation between increased MBCs is sta-
tistically significant, reduced susceptibility to both compounds
should have the same molecular mechanism. So far, our data
showed that this is not linked to the presence of qac genes, and
preliminary data on four strains also exclude upregulation of
other known efflux systems. This leaves the issue of the molecular
mechanism of increased biocide MBC in staphylococci open to
speculation.
This analysis of 1,602 isolates for MIC and MBC, the largest set
of staphylococcal strains ever analyzed, was unable to uncover a
clear indication of an ECOFF (38) or breakpoint for resistance to
both benzalkonium chloride and chlorhexidine. In contrast,
ethidium bromide screening showed a clear cutoff between a sus-
ceptible S. aureus population and nonsusceptible strains and a
perfect match to the presence of qacA and qacB genes (6). This is in
keeping with efflux pump overexpression being effective for com-
pounds acting inside the cell and being less effective on biocides
targeting the membrane(s) and acting from outside the cell (20).
Our recent analysis of triclosan susceptibility using the same set of
isolates showed a clear ECOFF for triclosan (22). No correlation of
reduced susceptibility to triclosan and benzalkonium chloride and
chlorhexidine (coresistance) was detected in our data set, even if
recent reports have identified plasmids carrying both qacA and the
newly described sh-fabI allele (22, 39, 40).
European legislation on biocide registration is changing, and a
test for risk assessment for biocide resistance has been proposed.
In this context, we have investigated the correlation between the
molecular nature of reduced susceptibility in clinical isolates and
mutations selected in vitro. We selected S. aureus mutants with
reduced susceptibility to a series of compounds, all previously
linked to efflux by the NorA efflux pump. In our assays, mutants
with reduced susceptibility could be selected by all compounds,
although the biocides required multiple passages. All mutants
showed mutations in the norA promoter region and the same
efflux phenotype. As observed in clinical isolates in our in vitro
mutants, ethidium bromide and acriflavine susceptibility profiles
changed significantly, while those for benzalkonium chloride and
chlorhexidine were quite similar to those of wild-type strains (6).
The fact that mutations conferred only a limited increase in resis-
tance to biocides is the most probable reason for the failure to
select, with a standard one-step protocol, mutants with these bio-
cides. Of the 14 clinical isolates in which we had found polymor-
phisms in the promoter region of norA, eight evidenced short
direct repeats in the promoter region (12). In contrast, in our in
vitro mutant strains, these duplications were not present, even
though in vitro selection has been reported to occur (11). Among
the point mutations selected in vitro, only 14% (4/28) matched
those in clinical isolates, which in turn represented only 21% (3/
14) of the total number of mutated clinical isolates. These data
indicate quite clearly that an in vitro test, such as the one carried
out here, would have a very low predictive value for clinically
relevant reduced biocide susceptibility. Approaches involving
shorter contact times and, possibly, neutralization of the biocides
may be explored for further investigation into in vitro tests for
prediction of biocide resistance. So far, the most suggestive expla-
nation for the difference of mutations in vitro and in clinical iso-
lates is the absence of selective pressure for fitness in vitro. In the
absence of a validated fitness model, the killing of wax moth larvae
had been proposed to serve as a fitness assay for biocide mutants in
staphylococci (26, 41). Even having screened 13 independent mu-A
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tants in three different S. aureus strains, we could not identify any
phenotype of reduced in vivo fitness.
In summary, our data show that 9.5% of clinical isolates of S.
aureus carry known genes associated with ethidium bromide ef-
flux and reduced susceptibility to biocides. Fine characterization
of the substrate specificity of these pumps associates (i) mutations
of the promoter region of norA with a 2-fold increase in MIC to
both benzalkonium chloride and chlorhexidine, (ii) the presence
of the plasmid-encoded MFS pumps QacA and QacB with a 4-fold
increase in MIC of benzalkonium chloride and 2-fold increase in
MIC of chlorhexidine, and (iii) the plasmid-encoded SMR efflux
pumps QacC and QacG with a 2-fold increase in MIC to benzalko-
nium chloride and no increase in MIC to chlorhexidine. Regard-
ing cross-resistance to antibiotics in vitro, mutation of the norA
promoter conferred cross-resistance to norfloxacin and cipro-
floxacin, but not all clinical isolates showing norA promoter mu-
tations were resistant to ciprofloxacin, and none of the plasmid-
encoded efflux pumps conferred resistance to antibiotics.
Importantly, data from clinical isolates has shown that none of
these determinants has any effect on the bactericidal activity of
biocides when using either CLSI assays or the EN 1276 norm. This
does not indicate that these transporters do not contribute to ef-
flux of their known substrates, but that the specific effect of these
MDR pumps is evidenced in S. aureus exclusively utilizing the
CLSI MIC growth inhibition assay. The importance given to the
cidal effect of biocides in many contexts, inducing the discussion
of their clinical relevance in selecting for antibiotic resistance, the
recommended in-use concentrations, which are far above the nat-
ural resistance of bacteria, and the planning of resistance surveys,
may have to be critically revised. At least in the specific case of
benzalkonium chloride and chlorhexidine and when using the S.
aureus model, we suggest focusing efforts only on MIC assays
when trying to correlate biocides and antibiotics susceptibility
profiles to the relative resistance genes during hazard evaluation
and risk assessments (2). Given our data, such a simplification is
completely justified and facilitates high-throughput screening.
The resulting increase in numbers and reduction in cost in the
presence of an unaltered capacity of resistance prediction will al-
low us to significantly speed up work on the risk evaluation of the
use of these compounds. On the other hand, our data suggest, with
regard to a possible introduction of tests for risk assessment for
benzalkonium chloride and chlorhexidine resistance in S. aureus,
that current in vitro tests for resistance development have a poor
predictive value and low clinical relevance.
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